Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes

JAMA Internal Medicine

Volumn 173, Issue 7, 2013, Pages 559-568

  Wright, Jason D ^a,c   Neugut, Alfred I ^a,b,c   Ananth, Cande V ^a   Lewin, Sharyn N ^a,c   Wilde, Elizabeth T ^a   Lu, Yu Shiang ^a   Herzog, Thomas J ^a,c   Hershman, Dawn L ^a,b,c  

^a Howard Hughes Medical Institute   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; DECISION MAKING; DEMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE FACILITY; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICIAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; FEVER; GUIDELINE ADHERENCE; HUMANS; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84876029694     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.2921     Document Type: Article

References (42)

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924.
2. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-2266.
3. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008;19(3):454-460.
4. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26(4):606-611.
5. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1(1):23-35.
6. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
7. National Comprehensive Cancer Network. Prevention and treatment of cancerrelated infections; 2009. http://www.nccn.org/professionals/physicians- gls/pdf/infections.pdf. Accessed January 14, 2013.
8. Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 Update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8-32.
9. National Comprehensive Cancer Network. Myeloid growth factors. 2010; v. 1.2010. http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf.
10. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-751.
11. Ozer H, Armitage JO, Bennett CL, et al; American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18(20):3558-3585.
12. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
13. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer. 2002;10(3):181-188.
14. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198-4214.
15. García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colonystimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31-38.
16. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapyinduced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(7):492-501.
17. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapyrelated febrile neutropenia. J Clin Oncol. 1996;14(2):619-627.
18. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against Grampositive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2005;55(4):436-444.
19. Abernethy AP, Barbour SY, Uronis H, et al. Quality management of potential chemotherapyinduced neutropenic complications: evaluation of practice in an academic medical center. Support Care Cancer. 2009;17(6):735-744.
20. Danova M, Rosti G, De Placido S, Bencardino K, Venturini M. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists. Oncol Rep. 2005;14(6):1405-1412.
21. Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer. 2008;16(2):181-191.
22. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359-2367.
23. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303(20):2035-2042.
24. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353(4):349-361.
25. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U. S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154(8):516-522.
26. Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control. 2006;17(5):647-654.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
28. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
29. Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology. 2007;69(5):871-875.
30. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245(5):777-783.
31. Aapro MS, Cameron DA, Pettengell R, et al; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433-2453.
32. Wright JD, Neugut AI, Wilde ET, et al. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol. 2011;29(25):3408-3418.
33. Ross JS, Normand SL, Wang Y, et al. Hospital volume and 30-day mortality for three common medical conditions. N Engl J Med. 2010;362(12):1110-1118.
34. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117-2127.
35. Lindenauer PK, Rothberg MB, Pekow PS, Kenwood C, Benjamin EM, Auerbach AD. Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med. 2007;357(25):2589-2600.
36. Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA. 2010;303(24):2479-2485.
37. Corbelli JC, Janicke DM, Cziraky MJ, Hoy TA, Corbelli JA. Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathways. Am Heart J. 2009;157(1):61-68.
38. Aziz EF, Pratap B, De Benedetti Zunino ME, et al. Success in implementing a hospitalwide evidence-based clinical pathways system for the management of cardiac patients: the ACAP program experience. Crit Pathw Cardiol. 2011;10(1):22-28.
39. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6) (suppl):381S-453S.
40. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977.
41. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital quality improvement. N Engl J Med. 2007;356(5):486-496.
42. Campion FX, Larson LR, Kadlubek PJ, Earle CC, Neuss MN. Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes. J Oncol Pract. 2011;7(3) (suppl):31s-35s.